Last Updated: June 9, 2026

Details for Patent: 6,098,632


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 6,098,632
Title:Nicotine-impermeable container and method of fabricating the same
Abstract:The present invention relates to a nicotine-impermeable container and a method for fabricating same. Additionally, the invention relates to a nicotine inhaling device which allows a user to ingest nicotine vapors orally. The nicotine inhaling device of the present invention is primarily directed to a device which can be used as a smoking cessation aid.
Inventor(s):James E. Turner, Michael P. Ellis, Ronald G. Oldham, Ira Hill, Bengt Eber Malmborg, Sven-Borje Andersson
Assignee: McNeil AB
Application Number:US08/803,555
Patent Claim Types:
see list of patent claims
Use; Compound; Delivery;
Patent landscape, scope, and claims:

United States Patent 6,098,632: Scope, Claim-Element Breakdown, and U.S. Landscape

What does US 6,098,632 claim in plain scope terms?

US 6,098,632 is directed to a nicotine delivery system that maintains nicotine integrity during storage (extended shelf life) by enclosing a measured nicotine reservoir in a self-sealed, nicotine-impermeable barrier. The barrier’s nicotine-blocking function comes from a copolymer-based nicotine barrier layer and from continuous sealing geometry created by heat-sealing at least two adjacent surfaces of the barrier layer.

Core claim architecture is consistent across independent claim 1 through claim 3, with claim scope differing by the copolymer state/structure used to form the nicotine barrier layer:

  • Claim 1: barrier layer is formed essentially of a copolymer (generic formulation).
  • Claim 2: barrier layer is formed essentially of a non-crystalline copolymer.
  • Claim 3: barrier layer is formed essentially of an amorphous copolymer.

Each claim adds the same functional and structural limitations:

  1. a nicotine reservoir (holds and disperses a measured amount),
  2. a self-sealed nicotine-impermeable barrier enclosing the reservoir,
  3. at least one nicotine barrier layer made from the specified copolymer class, and
  4. barrier continuity created by heat-sealing at least two adjacent surfaces to form a continuous nicotine-impermeable barrier, preventing nicotine migration outside.

What are the exact claim elements and how they constrain infringement?

Below is an element-by-element mapping for claims 1 to 3, organized for FTO and design-around analysis.

Claim 1 element map (copolymer in general)

Claim 1 requires all of the following:

  1. Nicotine delivery system with extended shelf life

    • Contains a measured amount of nicotine.
    • Nicotine can be “selectively made accessible to a user.”
  2. Nicotine reservoir

    • Holds and disperses the measured nicotine.
  3. Self-sealed, nicotine impermeable barrier enclosing the reservoir

    • The barrier encloses the nicotine reservoir.
    • The barrier is “self-sealed” and “nicotine impermeable.”
  4. Barrier layer material: copolymer effective in deterring nicotine migration

    • At least one nicotine barrier layer is formed essentially of a copolymer.
    • The copolymer is “effective in deterring nicotine migration.”
  5. Heat-sealed continuous barrier

    • The barrier layer includes at least two adjacent surfaces that are heat sealed.
    • Heat sealing forms a “continuous nicotine impermeable barrier.”
    • That barrier prevents nicotine migration outside the barrier.

Claim 2 element map (non-crystalline copolymer)

Claim 2 is identical to claim 1 except for this material limitation:

  • Barrier layer must be formed essentially of a non-crystalline copolymer effective in deterring nicotine migration.

Claim 3 element map (amorphous copolymer)

Claim 3 is identical to claim 1 except for this material limitation:

  • Barrier layer must be formed essentially of an amorphous copolymer effective in deterring nicotine migration.

Practical infringement boundary: where infringement is easiest vs. hardest

Easiest to land on:

  • Products using a sealed nicotine unit with copolymer-based nicotine barrier film and heat-sealed seam construction to create a continuous impervious enclosure.

Harder to land on:

  • Designs that avoid either:
    • the copolymer barrier layer requirement, or
    • heat-sealed adjacent surfaces forming a continuous barrier, or
    • the barrier being self-sealed, or
    • the copolymer being specifically non-crystalline or amorphous (as relevant to claims 2 and 3).

How broad are claims 1 to 3 relative to each other?

Claims 2 and 3 narrow claim 1 by specifying polymer morphology/structure.

Relative scope ranking

  • Claim 1 (broadest): “copolymer” effective at deterring migration.
  • Claim 2 (narrower): requires “non-crystalline copolymer.”
  • Claim 3 (narrower still in structure): requires “amorphous copolymer.”

In practical claim construction, claims 2 and 3 typically cover subsets of copolymers within claim 1’s general category. Claim 1 can read on both crystalline and non-crystalline materials unless “formed essentially of a copolymer” is interpreted narrowly by the intrinsic record (not provided here). Claims 2 and 3 impose explicit morphology limits that can be used for design-around via polymer crystallinity control and characterization.

What design choices can move a product outside the asserted scope?

The claim language provides several clean, technically actionable “outs.” The most direct are structural/material disconnects.

Design-around levers aligned to claim limitations

  1. Avoid a copolymer nicotine barrier layer

    • Use a barrier layer based on a different class (the claim requires “copolymer” or “non-crystalline/amorphous copolymer” depending on the asserted claim).
  2. Avoid heat sealing of at least two adjacent surfaces to form a continuous barrier

    • If the barrier’s continuity is achieved by other seam-closure mechanisms (adhesives, mechanical interlocks, solvent bonding, ultrasonic bonding) the infringement question turns on whether those methods are still “heat sealed,” which the literal claim language targets.
  3. Avoid “self-sealed” barrier enclosure

    • The “self-sealed” requirement can be a major boundary if packaging uses external seals or a separate sealing step rather than self-sealing structure.
  4. For claim 2 and claim 3, control polymer morphology

    • If the barrier copolymer is neither “non-crystalline” nor “amorphous” (as defined by crystallinity/amorphous fraction and characterization method), claims 2 or 3 may not apply even if claim 1 could.

How the “selectively accessible” nicotine concept affects claim reach

All three claims start with a nicotine delivery system where nicotine is selectively made accessible to a user. The claim text provided does not require a specific delivery mechanism (e.g., wick, membrane, mechanical puncture, diffusion-limited opening). This means the delivery “access” limitation likely functions as an intended use constraint rather than a detailed structural component, unless the patent specification ties it to a particular structure.

From an infringement standpoint, the strongest enforceable portion is the sealed reservoir and barrier architecture: reservoir + self-sealed nicotine-impermeable barrier + copolymer barrier layer + heat-sealed continuous seam preventing migration.

Claim-structure implications for claim construction

Two features often drive scope in barrier patents:

  1. “Nicotine impermeable barrier” plus functional “prevent migration outside the barrier”

    • The claim includes both a characterization (“nicotine impermeable”) and a functional outcome (“so that nicotine can be prevented from migration outside”).
    • This can broaden interpretation to barriers that meet the function even if exact “impermeable” thresholds are debated.
  2. Material phrasing: “formed essentially of”

    • “Essentially of” suggests tolerances: the barrier layer can include additives or minor fractions while still being “essentially” copolymer.
    • That tends to reduce strict material purity workarounds.

What does this imply for a freedom-to-operate posture?

Given only the claim language provided, US 6,098,632 is best treated as a seam-sealed, copolymer-barrier nicotine enclosure patent. The highest-risk overlap typically comes from products that:

  • store measured nicotine in an enclosed chamber;
  • use a polymeric barrier layer designed for nicotine migration reduction; and
  • create barrier continuity through heat-sealed adjacent surfaces.

If a nicotine pouch, cartridge, or micro-reservoir uses these same architectural elements, the probability of mapping to claims 1 to 3 increases quickly.

U.S. patent landscape: how this patent typically clusters

You asked for a “patent landscape,” but the only concrete source material provided is the claim text. Without bibliographic data (assignee, filing date, related patents/citations) the landscape cannot be accurately enumerated.

Per your constraints, a complete and accurate landscape requires external patent-record data (publication history, CPC/US class mapping, prosecution history, cited references, and family members). No such record data was provided in the prompt, so a definitive landscape cannot be produced without risking factual errors.

Actionable risk map derived from the claims

Even without a full landscape of neighboring patents, you can operationalize a risk map based on the elements US 6,098,632 demands.

Risk tiers by product architecture

Product architecture element If it matches the claim Risk tier
Nicotine reservoir holds a measured nicotine dose Yes High
Nicotine is enclosed in a self-sealed nicotine-impermeable barrier Yes High
Barrier layer is copolymer-based and blocks nicotine migration Yes High
Barrier seam created by heat sealing adjacent surfaces into a continuous barrier Yes High
Barrier copolymer is non-crystalline (claim 2) Yes Medium-High
Barrier copolymer is amorphous (claim 3) Yes Medium-High

Design-around target matrix

Claim limitation Primary design response
Copolymer barrier layer Swap polymer system away from copolymer-based barrier
Non-crystalline/amorphous barrier layer Use a copolymer that is not non-crystalline/amorphous (as characterized)
Heat-sealed adjacent surfaces for continuity Use non-heat seam closure or different sealing architecture
Self-sealed barrier enclosure Use separately sealed packaging architecture

Key Takeaways

  • US 6,098,632 claim scope centers on a sealed nicotine reservoir protected by a self-sealed nicotine-impermeable barrier that includes a copolymer-based nicotine barrier layer and a continuous heat-sealed seam that blocks nicotine migration.
  • Claim 1 is the broadest (copolymer effective against migration).
  • Claim 2 and claim 3 narrow by polymer morphology: non-crystalline and amorphous copolymers, respectively.
  • The most direct design-around routes are material class (copolymer barrier), seam-formation method (heat-sealed adjacent surfaces), and polymer morphology for claims 2 and 3.

FAQs

1) Does the patent require a specific nicotine dispensing mechanism?

The provided claims require nicotine is “selectively made accessible to a user,” but the provided limitations focus on the sealed reservoir and nicotine barrier architecture rather than specifying a particular dispensing structure.

2) What is the single most critical structural element for infringement risk?

The combination of (i) a self-sealed nicotine-impermeable barrier, (ii) a copolymer barrier layer effective to deter migration, and (iii) heat sealing of at least two adjacent surfaces to form a continuous barrier.

3) If a product uses a copolymer barrier but does not heat-seal adjacent surfaces, does it avoid the claims?

The claims explicitly require heat sealing of at least two adjacent surfaces to form a continuous nicotine-impermeable barrier. Avoiding that seam method is a direct path to non-infringement on that limitation.

4) How do claims 2 and 3 change enforcement compared with claim 1?

Claims 2 and 3 impose morphology constraints on the copolymer barrier layer: “non-crystalline” and “amorphous,” respectively. This can reduce coverage for barriers whose polymer structure does not fit those categories.

5) Is the “extended shelf life” limitation likely to narrow claim coverage?

The claims include the shelf-life concept but do not add quantified shelf-life metrics or process steps in the provided claim language. The enforceable limitations remain the sealed nicotine reservoir and barrier structure.


References

[1] United States Patent 6,098,632, claims 1-3 (as provided in prompt).

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 6,098,632

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.